Drug Payers Prefer Comparative Effectiveness Data Over Clinical Trial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
The data most often requested of drug manufacturers by healthcare
payers, and those they find to be the most effective, are comparative
effectiveness data and budget impact models.

According to surveyed HOL
teams in a Cutting Edge Information’s report, “Advanced Health
Outcomes Liaison and Managed Care Liaison Teams: Delivering Health
Economics and Clinical Data To Payers,” the two questions payers ask
when evaluating a drug are:

1. Is this drug more effective than the competitors?

2. How will it affect our budget?

Clinical trial results fall to the bottom of HOLs’ priority lists
because payers are not as interested in efficacy results that come from
such a sterile clinical environment. Payers prefer comparative
data, such as head-to-head studies, and real-world use data over
clinical trial results.

The report details payers’ needs and how HOL teams are structured to
meet them. It also found that in countries with single-payer systems,
such as Canada and the United Kingdom, payers differ in their product
data preference. Cost-effectiveness
assessments are most impactful when speaking with Canadian and UK
payers.

This preference points to Canadian and UK payers’ emphasis on drug cost,
not just efficacy. “In an effort to contain costs and be able to provide
universal healthcare, prescription costs — including long-term costs
linked to different health outcomes — must be key factors in any
reimbursement decision,” said Nicole May, research analyst at Cutting
Edge Information. In both cases, with the exception of an interviewed US
biologic company, clinical trial results ranked last on these payers’
lists of data preferences.

The study “Advanced Health Outcomes Liaison and Managed Care Liaison
Teams: Delivering Health Economics and Clinical Data To Payers,”
available at (http://www.cuttingedgeinfo.com/research/medical-affairs/health-outcomes-...),
includes staffing and budget metrics to help companies build their HOL
and MCL functions. Health economics teams and medical affairs executives
can use this report to:

For more information about health
outcomes liaison management, contact Cassie Demeter at 919-403-6583.

Cutting Edge InformationCassie Demeter, 919-403-6583

Source: Cutting Edge Information